FORT WASHINGTON, Pa. & INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim and Vitae Pharmaceuticals, Inc., announced today that they have established a major collaboration to develop and commercialize 11beta-HSD1 inhibitors. Compounds which inhibit 11beta-HSD1, an enzyme involved in cortisol production, may have utility in the treatment of diabetes and metabolic syndrome related diseases, including obesity, dyslipidemia and hypertension. The companies will combine their respective 11beta-HSD1 programs and work together to identify and advance candidates for clinical development.
